Have a personal or library account? Click to login
Platinum Complexes And Their Anti-Tumour Activity Against Chronic Lymphocytic Leukaemia Cells Cover

Platinum Complexes And Their Anti-Tumour Activity Against Chronic Lymphocytic Leukaemia Cells

EABR. Experimental and Applied Biomedical Research
Volume 16 (2015): Issue 3 (September 2015)
By: Žana Besser Silconi,  Sasa Benazic,  Jelena Milovanovic,  Aleksandar Arsenijevic,  Bojana Stojanovic,  Marija Milovanovic and  Tatjana Kanjevac  
Open Access
|Oct 2015

References

  1. 1. Jakupec MA, Galanski M, Arion VB, Hartinger CG & Keppler BK. (2008). Antitumor metal compounds: more than theme and variations. Dalton Trans. 14;(2), 183-194.10.1039/B712656P18097483
    Search in Google Scholar
  2. 2. Florea A & Büsselberg D. (2001). Cisplatin as an Anti-Tumor Drug: Cellular Mechanisms of Activity, Drug Resistance and Induced Side Effects. Cancers. 15;3(1), 1351-1371.10.3390/cancers3011351375641724212665
    Search in Google Scholar
  3. 3. Oun R. & Wheate NJ. (2013). Platinum Anticancer Drugs. In: Kretsinger RH, Uversky VN & Permiyakov EA. Encyclopedia of Metalloproteins (pp.1710-1714). New York, Heidelberg, Dordrecht, London:Springer.
    Search in Google Scholar
  4. 4. Arnesano F. (2013). Platinum Complexes and Methionine Motif in Copper Transport Proteins Interaction In: Kretsinger RH, Uversky VN & Permiyakov EA. Encyclopedia of Metalloproteins (pp.1714-1723). New York, Heidelberg, Dordrecht, London:Springer.
    Search in Google Scholar
  5. 5. Kostova I. (2006). Platinum Complexes as Anticancer Agents. Recent Pat Anticancer Drug Discov. 1(1), 1-22.10.2174/15748920677524645818221023
    Search in Google Scholar
  6. 6. Swerdlow SH, Campo E, Haris NL, Jaffe ES, Poleri SA, Stein H, Thiele J & Vardiman JW. (2008). WHO Classification of Tumours of Haematopoetic and Lymphoid Tissues. (4th ed.) (pp 180-184). Lyon: International Agency for Research on Cancer.
    Search in Google Scholar
  7. 7. Aster JC. (1999). Diseases of white blood cells, lymph nodes, spleen, and thymus In: Kumar V, Abbas AK & Fausto N. Robbins and Cotran, Pathologic basis of disease (7th ed.) (pp 661-709). Philadelphia: Elsevier Saunders.
    Search in Google Scholar
  8. 8. Nahi H, Lehman S, Mollgard L, Bengtzen S, Selivanova G, Wiman KG, Paul C & Merup M. (2004). Effects oh PRIMA-1 on chronic lymphocytis leukaemia cells with and without hemizygous p53 deletion. Br J Haematol. 127(3), 285-291.10.1111/j.1365-2141.2004.05210.x15491287
    Search in Google Scholar
  9. 9. Binet JL, Caligaris-Cappio F, Catovsky D, Cheson Bruce, Davis T, Dighiero G, Döhner H, Hallek M, Hillmen P, Keating M, Montserrat E, Kipps TJ & Rai K. (2006). Perspectives on the use of new diagnostic tools in the treatment of chronic lymphocytic leukemia. Blood. 107(3), 859-861.10.1182/blood-2005-04-167716223776
    Search in Google Scholar
  10. 10. Chastain EC & Duncavage EJ. (2015). Clinical Prognostic Biomarkers in Chronic Lymphocytic Leukemia and Diffuse Large B-Cell Lymphoma. Arch Pathol Lab Med. 139(5), 602-607.10.5858/arpa.2014-0086-RA25248094
    Search in Google Scholar
  11. 11. Caligaris-Cappio F. (2009). Chronic lymphocytic leukemia: “Cinderella” is becoming a star. Mol Med. 15(3-4), 67-69.10.2119/molmed.2008.00126260049719081769
    Search in Google Scholar
  12. 12. Rai KR, Sawitsky A, Cronkite EP, Chanana AD, Levy RN & Pasternack BS. (1975). Clinical staging of chronic lymphocytic leukemia. Blood. 46, 219-234.10.1182/blood.V46.2.219.219
    Search in Google Scholar
  13. 13. Binet JL, Auquier A, Dighiero G, Chastang C, Piguet H, Goasguen J, Vaugier G, Potron G, Colona P, Oberling F, Thomas M, Tchernia G, Jacquillat C, Boivin P, Lesty C, Duault MT, Monconduit M, Belabbes S & Gremy F. (1981). A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer. 48: 198-206.
    Search in Google Scholar
  14. 14. Vujić JM, Kaluđerović GN, Zmejkoviski BB, Milovanović M, Volarević V, Arsenijević N, Stanojković TP & Trifunović S. (2012). Stereospecific ligands and their complexes: Part X: Syntesis, characterization and in vitro antitumoral activity of platinum (IV) complexes with O,O′-dialkyl-(S,S)-ethylenediamine-N,N′-di-2-(4-methyl) pentanoate ligands. Inorganica Chimica Acta. 390, 123-128.10.1016/j.ica.2012.03.048
    Search in Google Scholar
  15. 15. Habashi F. (2013) Platinum, Physical and Chemical Properties In: Kretsinger RH, Uversky VN & Permiyakov EA. Encyclopedia of Metalloproteins (pp.1741-1742). New York, Heidelberg, Dordrecht, London:Springer.10.1007/978-1-4614-1533-6_422
    Search in Google Scholar
  16. 16. Palm-Espling ME & Wittung-Stafshede P. (2013) Platinum Interaction with Copper Proteins. In: Kretsinger RH, Uversky VN & Permiyakov EA. Encyclopedia of Metalloproteins (pp.1723-1729). New York, Heidelberg, Dordrecht, London:Springer.10.1007/978-1-4614-1533-6_534
    Search in Google Scholar
  17. 17. Arsenijević M, Milovanović M, Volarević V, Čanović D, Arsenijević N, Soldatović T, Jovanović S & Bugarčić ŽD. (2012). Cytotoxic properties of platinum(IV) and dinuclear platinum (II) complexes and their ligand substitution reactions with guanosine-5′-monophosphate. Transition Metal Chemistry. 37: 481-488.
    Search in Google Scholar
  18. 18. Vujić JM, Kaluđerović GN, Milovanović M, Zmejkoviski BB, Volarević V, Živić D, Đurđević P, Arsenijević N & Trifunović S. (2011). Stereospecific ligands and their complexes: Part VII Syntesis, characterization and in vitro antitumoral activity of platinum(II) complexes with O,O′-dialkyl esters of (S,S)-ethylenediamine-N,N′-di-2-(4-methyl) pentanoic acid. Eur J Med Chem. 46(9), 4559-4565.10.1016/j.ejmech.2011.07.03421840630
    Search in Google Scholar
  19. 19. Cepeda V, Fuertes MA, Castilla J, Alonso C, Quevedo C & Peres JM. (2007). Biochemical Mechanisms of Cisplatin Cytotoxicity. Anticancer Agents Med Chem. 7(1), 3-18.10.2174/18715200777931404417266502
    Search in Google Scholar
  20. 20. Gately DP & Howel SB. (1993). Cellular accumulation of the anticancer agent cisplatin: A review. Br J Cancer. 67(6), 1171-1176.10.1038/bjc.1993.22119685228512802
    Search in Google Scholar
  21. 21. Bordin DL, Lima M, Lenz G, Saffi J, Meira LB, Paul Mésange P, Soares DH, Larsen AK, Escargueil AE & Henriques JAP. (2013). DNA alkylation damage and autophagy induction. Mutat Res. 753(2), 91-99.10.1016/j.mrrev.2013.07.00123872363
    Search in Google Scholar
  22. 22. Blair BG, Larson CA & Howell SB. (2009). Copper-Transporter 2 Regulates the Cellular Accumulation and Cytotoxicity of Cisplatin and Carboplatin. Clin Cancer Res. 15(13), 4312-4321.10.1158/1078-0432.CCR-09-0311286264019509135
    Search in Google Scholar
  23. 23. Silaghi-Dumitrescu R & Bischin C. (2013). Platinum-Containing Anticancer Drugs and Proteins, Interaction In: Kretsinger RH, Uversky VN & Permiyakov EA. Encyclopedia of Metalloproteins (pp.1742-1748). New York, Heidelberg, Dordrecht, London: Springer.
    Search in Google Scholar
  24. 24. Kampfenkel K, Kushnir S, Babiychuk E, Inze` D & Van Montagu M. (1995). Molecular Characterization of a Putative Arabidopsis thaliana Copper Transporter and Its Yeast Homologue. J Biol Chem. 270(47), 28479-28486.10.1074/jbc.270.47.284797499355
    Search in Google Scholar
  25. 25. Eckstein N & Hass B. (2013). Platinum-Resistant Cancer In: Kretsinger RH, Uversky VN & Permiyakov EA. Encyclopedia of Metalloproteins (pp.1748-1751). New York, Heidelberg, Dordrecht, London: Springer.
    Search in Google Scholar
  26. 26. Boulikas T, Pantos A, Bellis E & Christofis P. (2007). Designing platinum compounds in cancer: structures and mechanism. Cancer Therapy. 5, 537-583.
    Search in Google Scholar
  27. 27. Gonzales VM, Fuertes MA, Alonso C & Perez JM. (2001). Is Cisplatin-Induced Cell Death Always Produced by Apoptosis? Mol Pharmacol. 59(4), 657-63.
    Search in Google Scholar
  28. 28. Ashkenazi A & Herbst R.S. To kill a tumor cell: the potential of proapoptotic receptor agonists. The Journal of Clinical Investigation 2008; 118(8): 1979-1990.
    Search in Google Scholar
  29. 29. Del Bello B, Valentini MA, Yunino F, Comporti M & Maellaro E. (2001). Cleavage of Bcl-2 and cisplatin-induced apoptosis of human melanoma cells. Onkogene. 20(33), 4591-4595.10.1038/sj.onc.120461811494156
    Search in Google Scholar
  30. 30. Müller M, Wilder S, Bannasch D, Israeli D, Lehlbach K, Li-Weber M, Friedman SL, Galle PR, Stremmel W, Oren M & Krammer PH. (1998). p53 activates the CD95 (APO-1/Fas) gene in response to DNA damage by anticancer drugs. J Exp Med. 188(11), 2033–2045.10.1084/jem.188.11.203322123869841917
    Search in Google Scholar
  31. 31. Reed E. ERCC1 and clinical resistance to platinum-based therapy. Clin Cancer Res.11(17), 6100-6102.10.1158/1078-0432.CCR-05-108316144907
    Search in Google Scholar
  32. 32. Alderden AA, Hall M D. & Hambley TW. (2006). The discovery and Development of Cisplatin. J Chem Educ. 83(5), 728-734.10.1021/ed083p728
    Search in Google Scholar
  33. 33. Bou Samra E, Klein B, Commes T & Moreaux J. (2014). Identification of a 20-gene expression-based risk score as a predictor of clinical outcome in chronic lymphocytic leukemia patients. Biomed Res Int. 2014, 423174.10.1155/2014/423174402684924883311
    Search in Google Scholar
  34. 34. Tonino SH, van Gelder M, Eldering E, van Oers MH & Kater AP. R-DHAP is effective in fludarabine-refractory chronic lymphocytic leukemia. Leukemia. 24(3), 652-654.10.1038/leu.2009.24019956201
    Search in Google Scholar
  35. 35. Tonino SH, van Laar J, van Oers MH, Wang JY, Eldering E & Kater AP. (2011). ROS-mediated upregulation of Noxa overcomes chemoresistance in chronic lymphocytic leukemia. Oncogene. 30(6), 701-713.10.1038/onc.2010.441399540920935673
    Search in Google Scholar
  36. 36. Zecevic A, Sampath D, Ewald B, Chen R, Wierda W & Plunkett W. (2011). Killing of chronic lymphocytic leukemia by the combination of fludarabine and oxaliplatin is dependent on the activity of XPF endonuclease. Clin Cancer Res. 17(14), 4731-4741.10.1158/1078-0432.CCR-10-2561553434221632856
    Search in Google Scholar
DOI: https://doi.org/10.1515/sjecr-2015-0023 | Journal eISSN: 2956-2090 | Journal ISSN: 2956-0454
Journal RSS Feed
Language: English
Page range: 181 - 186
Submitted on: Jul 14, 2015
|
Accepted on: Jul 27, 2015
|
Published on: Oct 14, 2015
Published by: University of Kragujevac, Faculty of Medical Sciences
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year
Keywords:
Platinum-based anticancer drugs,
Chronic lymphocytic leukaemia,
Cisplatin mechanisms of action,
Cancer treatment
Related subjects:
Medicine,
Clinical medicine,
Clinical medicine, other

© 2015 Žana Besser Silconi, Sasa Benazic, Jelena Milovanovic, Aleksandar Arsenijevic, Bojana Stojanovic, Marija Milovanovic, Tatjana Kanjevac, published by University of Kragujevac, Faculty of Medical Sciences
This work is licensed under the Creative Commons Attribution 4.0 License.

Volume 16 (2015): Issue 3 (September 2015)Next article